Industry Analysis & Industry Trends
With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience a boost in demand. Rising production of branded follow-on biologic drugs will be important in offsetting the effects of widespread patent expirations, though a major increase in taxes and discounts to fill the Medicare coverage gap threatens profit in the industry... purchase to read more
Industry Report - Industry Analysis Chapter
Demand for Brand Name Pharmaceutical Manufacturing industry products has been boosted by an aging population and the use of prescription drugs as an integral part of US healthcare. Despite these favorable trends, the industry has suffered alongside the rest of the economy, with numerous brand blockbusters losing patent exclusivity, reducing revenue 8.5% in 2010.
Revenue is expected to slightly increase at an average annual rate of 1.5% to $165.0 billion during the five years to 2013, although revenue will drop 2.0% in 2013 as the industry's major players cope with losing patent protection for top-selling drugs. The number of new drugs reaching the market has been falling, driving industry players to focus on different areas of production to increase sales... purchase to read more